IDEXX Laboratories, Inc. (IDXX)
NASDAQ: IDXX · Real-Time Price · USD
554.99
+9.91 (1.82%)
Aug 28, 2026, 4:00 PM EDT - Market closed
IDEXX Laboratories Employees
IDEXX Laboratories had 11,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
11,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$413,929
Profits / Employee
$103,605
Market Cap
43.72B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11,000 | 0 | - |
| Dec 31, 2024 | 11,000 | 0 | - |
| Dec 31, 2023 | 11,000 | 220 | 2.04% |
| Dec 31, 2022 | 10,780 | 430 | 4.15% |
| Dec 31, 2021 | 10,350 | 1,050 | 11.29% |
| Dec 31, 2020 | 9,300 | 100 | 1.09% |
| Dec 31, 2019 | 9,200 | 823 | 9.82% |
| Dec 31, 2018 | 8,377 | 777 | 10.22% |
| Dec 31, 2017 | 7,600 | 235 | 3.19% |
| Dec 31, 2016 | 7,365 | 565 | 8.31% |
| Dec 31, 2015 | 6,800 | 400 | 6.25% |
| Dec 31, 2014 | 6,400 | 700 | 12.28% |
| Dec 31, 2013 | 5,700 | 300 | 5.56% |
| Dec 31, 2012 | 5,400 | 300 | 5.88% |
| Dec 31, 2011 | 5,100 | 300 | 6.25% |
| Dec 31, 2010 | 4,800 | 0 | - |
| Dec 31, 2009 | 4,800 | 100 | 2.13% |
| Dec 31, 2008 | 4,700 | 0 | - |
| Dec 31, 2007 | 4,700 | 800 | 20.51% |
| Dec 31, 2006 | 3,900 | 600 | 18.18% |
| Dec 31, 2005 | 3,300 | 305 | 10.18% |
| Dec 31, 2004 | 2,995 | 522 | 21.11% |
| Dec 31, 2003 | 2,473 | 292 | 13.39% |
| Dec 31, 2002 | 2,181 | 11 | 0.51% |
| Dec 31, 2001 | 2,170 | -80 | -3.56% |
| Dec 31, 2000 | 2,250 | 200 | 9.76% |
| Dec 31, 1999 | 2,050 | -50 | -2.38% |
| Dec 31, 1998 | 2,100 | 0 | - |
| Dec 31, 1997 | 2,100 | 585 | 38.61% |
| Dec 31, 1996 | 1,515 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IQVIA Holdings | 93,000 |
| Labcorp Holdings | 71,000 |
| Quest Diagnostics | 57,000 |
| Agilent Technologies | 18,100 |
| Mettler-Toledo International | 18,100 |
| Revvity | 11,000 |
| Illumina | 10,080 |
| Waters | 7,900 |
IDXX News
- 15 days ago - IDEXX Laboratories Transcript: Investor Day 2026 - Transcripts
- 15 days ago - IDEXX Laboratories Slides: FY 2026 - Filings
- 17 days ago - Idexx Laboratories announces launch of Catalyst proBNP Test - TheFly
- 17 days ago - IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test - Business Wire
- 17 days ago - Idexx Laboratories price target lowered to $710 from $800 at Barclays - TheFly
- 23 days ago - Idexx Laboratories price target raised to $670 from $620 at UBS - TheFly
- 23 days ago - Idexx Laboratories price target raised to $670 from $650 at Citi - TheFly
- 24 days ago - Idexx Laboratories reports Q2 EPS $4.27, consensus $3.93 - TheFly